Tender detail
Ranibizumab rebate agreements
Summary
The tender concerns the supply or contractual offering of ranibizumab medicines under open-house biologics rebate agreements. The contract can be concluded by all suitable pharmaceutical companies on uniform terms; no individual negotiations are held and no exclusivity is granted. The contract term is up to 12 months starting on 01/11/2025 and ends no later than 31/10/2026. Joining is possible at any time during the contract period.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.